Research programme: bispecific antibodies - Notable Labs
Alternative Names: VB-600 bi-specific antibody seriesLatest Information Update: 07 Jun 2024
At a glance
- Originator VBL Therapeutics
- Developer Notable Labs
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for preclinical development in Solid-tumours in Israel (Parenteral)